文献速递小儿眼科与斜弱视

肉毒毒素与斜视手术治疗儿童急性获得性共同性内斜视的三年结局

Three-year Outcomes of Botulinum Toxin Versus Strabismus Surgery for the Treatment of Acute Acquired Comitant Esotropia in Children.
PubMed 文献 · Am J Ophthalmol · 2025-01-03

这项多中心回顾性非随机对照非劣效性研究纳入76例儿童急性获得性共同性内斜视患者,比较肉毒毒素注射与斜视手术的36个月成功率。结果显示肉毒毒素组成功率72%、手术组56%,肉毒毒素不劣于手术,且全麻时间与麻醉恢复室停留时间更短。从内斜视发病到任何干预的中位时间越长,感觉运动结局越差。

要点

  • 肉毒毒素组36个月成功率72%,手术组56%,肉毒毒素不劣于手术(成功率差值95%CI -5%至+38%)。
  • 肉毒毒素组全麻时间6分钟 vs 手术组71分钟(P < .0001),麻醉恢复室时间40分钟 vs 95分钟(P < .0001)。
  • 36个月时治疗成功者从发病到干预中位时间4个月,未成功者6.5个月(P < .05)。

核心结论

  • 肉毒毒素在治疗儿童急性获得性共同性内斜视36个月时不劣于斜视手术,同时缩短全麻时间。
  • 从内斜视发病到治疗的时间延迟较长是感觉运动结局较差的独立危险因素,与治疗类型无关。

研究设计与样本

  • 多中心、回顾性、非随机、对照、临床非劣效性研究,设置于两家三级儿科医院。
  • 研究人群为76例急性获得性共同性内斜视儿童,治疗后随访至少36个月。
  • 干预为肉毒毒素治疗(肉毒毒素组)或斜视手术(手术组)。
  • 主要结局指标为36个月成功率,定义为水平偏斜≤10棱镜度且存在双眼视。

主要发现

  • 肉毒毒素组44例,手术组32例,两组中位偏斜度均为35棱镜度(范围10-55)。
  • 肉毒毒素组全麻时间6分钟 vs 手术组71分钟(P < .0001),麻醉恢复室时间40分钟 vs 95分钟(P < .0001),肉毒毒素组显著更短。
  • 36个月时肉毒毒素组成功率72%,手术组56%,两组中位偏斜度和中位立体视锐度相似。
  • 肉毒毒素在36个月时不劣于手术,成功率差值(肉毒毒素减手术)95%CI为-5%至+38%。
  • 36个月时,治疗成功者从内斜视发病到任何干预的中位时间为4个月,未成功者为6.5个月(P < .05)。

关键数值与推荐

  • 36个月成功定义为水平偏斜≤10棱镜度且存在双眼视证据。
  • 非劣效性判断基于成功率差值(肉毒毒素减手术)95%CI -5%至+38%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Botulinum toxin is an alternative to conventional strabismus surgery for treatment of acute, acquired, comitant esotropia (AACE). Previous studies suggest that the 2 treatment approaches may be equally effective for 6 months. The purpose of our study was to determine whether botulinum toxin remains as effective as strabismus surgery for 36 months after treatment. DESIGN: Multicenter, retrospective, nonrandomized, comparative, clinical, noninferiority study. METHODS: Setting: Two tertiary care pediatric hospitals. STUDY POPULATION: 76 children with AACE followed for at least 36 months after treatment. INTERVENTION: Treatment with either botulinum toxin ("BTX group") or strabismus surgery ("surgery group"). MAIN OUTCOME MEASURE: Success rate at 36 months (horizontal deviation of 10 prism diopters or less and evidence of binocular vision). RESULTS: There were 44 patients in the BTX group and 32 patients in the surgery group with a median deviation of 35 PD in both groups (range 10-55). The duration of general anesthesia (6 versus 71 min, P < .0001) and time in the postanesthesia care unit (40 versus 95 min, P < .0001) were significantly shorter in the BTX group. At 36 months, the success rate was 72% in the BTX group and 56% in the surgery group with a similar median deviation and median stereoacuity. BTX was noninferior to surgery at 36 months (95%CI for difference in success rate (BTX minus surgery) was -5% to +38%). At 36 months, the median time from esotropia onset to any intervention was 6.5 months without treatment success and 4 months in those with treatment success (P < .05). CONCLUSIONS/RELEVANCE: Botulinum toxin was noninferior to strabismus surgery in the treatment of AACE at 36 months while reducing the duration of general anesthesia. Longer delay from esotropia onset to treatment was an independent risk factor for worse sensorimotor outcomes irresepctive of the type of treatment.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Nguyen MTB, Cheung CSY, Hunter DG, et al. Three-year Outcomes of Botulinum Toxin Versus Strabismus Surgery for the Treatment of Acute Acquired Comitant Esotropia in Children. Am J Ophthalmol. 2025. PMID: 39755349. doi:10.1016/j.ajo.2024.12.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。